Semaglutide: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 43: | Line 43: | ||
Semaglutide, a GLP-1 receptor agonist, has demonstrated efficacy in weight loss and glycemic control but is often discontinued due to adverse effects and financial barriers. Real-world data reveal that 36.5% of patients discontinue GLP-1 agonists within 12 months, with higher rates among those with obesity compared to type 2 diabetes<ref>PMID: 38787563</ref>. Factors such as gastrointestinal side effects, out-of-pocket costs, and demographic disparities, including race and socioeconomic status, significantly contribute to discontinuation rates (Do et al., 2024). These findings highlight the need for balancing therapeutic benefits with patient tolerability and accessibility. | Semaglutide, a GLP-1 receptor agonist, has demonstrated efficacy in weight loss and glycemic control but is often discontinued due to adverse effects and financial barriers. Real-world data reveal that 36.5% of patients discontinue GLP-1 agonists within 12 months, with higher rates among those with obesity compared to type 2 diabetes<ref>PMID: 38787563</ref>. Factors such as gastrointestinal side effects, out-of-pocket costs, and demographic disparities, including race and socioeconomic status, significantly contribute to discontinuation rates (Do et al., 2024). These findings highlight the need for balancing therapeutic benefits with patient tolerability and accessibility. | ||
==Student contributors== | |||
This page was created as a two-week project of an undergraduate biochemistry course. Karsten Theis would like to acknowledge contributors to the Structure, Half-life and Side effects sections, Paige, Marissa, Faith, Will, Humzah, Mahrosha, Evelyn, Naba, Faiza, Sara, and Natalisha. | |||
== References == | == References == | ||
<references/> | <references/> | ||
